osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lcsm,(-blcsm)', 'lazertinib', '9006', 'sclc', 'nsclc', 'chrysalis-2', 'emd']
#asco22 abs #9006 shu et al. present data in egfrm #lcsm #nsclc with update of #chrysalis-2: amivantamab + lazertinib post osi/chemo shows: orr: 36%, mdor: nr- in cohort a 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own